This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

IMRIS And Stryker Are Working To Combine Efforts To Offer Auto-registration With Surgical Navigation In VISIUS ICT & IMRI Surgical Theaters

Workflow will be streamlined in navigated spinal and cranial procedures performed in advanced intraoperative imaging suites

MINNEAPOLIS, MN, and Kalamazoo, MI, Oct. 8, 2013 /PRNewswire/ - IMRIS Inc. ("IMRIS") and Stryker Corporation ("Stryker") today announced a non-exclusive collaboration between Stryker's automatic image registration for spinal and cranial navigated procedures and VISIUS ® iCT and VISIUS iMRI surgical suites from IMRIS.

"Having these tools work together is an exciting opportunity for surgeons utilizing intraoperative CT and MRI in our VISIUS ® Surgical Theatres. This open platform collaboration aligns squarely with our goal of providing state-of-the-art imaging at the point of therapy," said Jay D. Miller, IMRIS President and CEO.

IMRIS markets the VISIUS Surgical Theatre with intraoperative CT and MRI options to provide surgical teams with on-demand access to state-of-the-art, diagnostic quality imaging. The IMRIS solution makes these valuable images possible at key points in the surgery with patented technology that brings the scanner into the OR rather than requiring the surgeon to bring the patient to the scanner.

"We are excited to partner with IMRIS to bring streamlined surgical solutions into integrated CT and MRI capable operating rooms. IMRIS shares our open platform philosophy and we believe that through this partnership we will improve the surgeon experience," said Jim Marucci, Stryker Navigation General Manager.

This collaboration is focused on improving surgical precision, streamlining workflows and increasing visualization. The combined solution will support the growing trend toward minimally invasive spinal and cranial approaches that spare healthy tissue, reduce pain, and speed recovery for patients.

About IMRIS

IMRIS is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angio modalities accessed effortlessly in the operating room setting. VISIUS Surgical Theatres serve the neurosurgical, spinal, cardiovascular and cerebrovascular markets and have been selected by 54 leading medical institutions around the world.

About Stryker

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

SOURCE IMRIS Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7870 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs